Sleep Number Corporation heads into its Q1 2026 earnings release with one of the most aggressive short setups in the consumer sector.
Nearly 30% of the free float is short — a level that signals deep structural bearishness, not a passing hedge. Short interest climbed 6.4% over the past week and is up more than 21% over the past month, accelerating into the event. The borrow market has tightened dramatically alongside that build: cost to borrow quadrupled from roughly 1.6% at the start of April to 8.2% now, with a brief spike above 14% in early May. Availability has collapsed to near-zero — for the past week, essentially every share in the lending pool has been lent out, matching the 52-week extreme. That combination of rising short interest and evaporating borrow supply points to a market that is both heavily positioned to the downside and increasingly constrained in adding more.
Options positioning amplifies the cautious tone. The put/call ratio reached 1.24 on Tuesday — roughly 1.55 standard deviations above its 20-day average of 0.72. For context, the 52-week high is 1.55, so this reading is close to the most defensive options posture SNBR has seen in the past year. The stock itself fell 22% on Tuesday alone, extending a one-week decline of 27% to close at $1.90, even as a strong April had briefly lifted it 35% from prior lows. That reversal erases most of the recovery and lands the stock near record-low territory.
The analyst community has been consistently neutral — and consistently cutting targets. Following the company's last earnings in March, both UBS and Piper Sandler slashed price targets dramatically, UBS from $10 to $4 and Piper Sandler from $12 to $5. The mean analyst target now sits at $3.50, nearly double the current price. That gap is real — it reflects analysts pricing in a recovery scenario — but the direction of travel has been persistently downward for over a year, with no upgrades and multiple reductions at every earnings cycle. The last print delivered the clearest read on how the market reacts: shares fell 25% on the day and 38% over the following five days after March's Q4 release.
The institutional picture offers little counterweight. Stadium Capital holds 11.4% of shares as the largest institutional owner, unchanged through end of 2024. The most recent insider activity — a cluster of small sales by senior officers in mid-March at $3.45 — suggests no buying conviction from within at any recent price level.
What tonight's print will test is whether Sleep Number can show any credible path back toward positive cash generation and stabilised revenue, enough to challenge a short base that has now grown to its most entrenched position in years.
See the live data behind this article on ORTEX.
Open SNBR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
